Literature DB >> 18640748

New indications and controversies in arginine therapy.

David Coman1, Joy Yaplito-Lee, Avihu Boneh.   

Abstract

Arginine is an important, versatile and a conditionally essential amino acid. Besides serving as a building block for tissue proteins, arginine plays a critical role in ammonia detoxification, and nitric oxide and creatine production. Arginine supplementation is an essential component for the treatment of urea cycle defects but recently some reservations have been raised with regards to the doses used in the treatment regimens of these disorders. In recent years, arginine supplementation or restriction has been proposed and trialled in several disorders, including vascular diseases and asthma, mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS), glutaric aciduria type I and disorders of creatine metabolism, both production and transportation into the central nervous system. Herein we present new therapeutic indications and controversies surrounding arginine supplementation or deprivation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640748     DOI: 10.1016/j.clnu.2008.05.007

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  27 in total

1.  Increased serum levels of L-arginine in ulcerative colitis and correlation with disease severity.

Authors:  Shih-Kuang S Hong; Brad E Maltz; Lori A Coburn; James C Slaughter; Rupesh Chaturvedi; David A Schwartz; Keith T Wilson
Journal:  Inflamm Bowel Dis       Date:  2010-01       Impact factor: 5.325

2.  Dietary supplementation of some antioxidants against hypoxia.

Authors:  Sanaa Ahmed Ali; Hanan Farouk Aly; Lilla Mohammed Faddah; Zeenat F Zaidi
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

3.  8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease.

Authors:  Rebecca D Ganetzky; Marni J Falk
Journal:  Mol Genet Metab       Date:  2018-02-02       Impact factor: 4.797

4.  L-Arginine Availability and Metabolism Is Altered in Ulcerative Colitis.

Authors:  Lori A Coburn; Sara N Horst; Margaret M Allaman; Caroline T Brown; Christopher S Williams; Mallary E Hodges; Jennifer P Druce; Dawn B Beaulieu; David A Schwartz; Keith T Wilson
Journal:  Inflamm Bowel Dis       Date:  2016-08       Impact factor: 5.325

5.  A Case of Hyperargininaemia Presenting at Unusually Low Age.

Authors:  Vanita Lal; Daisy Khera; Garima Gupta; Kuldeep Singh; Praveen Sharma
Journal:  J Clin Diagn Res       Date:  2017-07-01

6.  Oral Supplementation with Beta-Hydroxy-Beta-Methylbutyrate, Arginine, and Glutamine Improves Lean Body Mass in Healthy Older Adults.

Authors:  Amy C Ellis; Gary R Hunter; Amy M Goss; Barbara A Gower
Journal:  J Diet Suppl       Date:  2018-04-19

7.  A novel mutation in TAZ causes mitochondrial respiratory chain disorder without cardiomyopathy.

Authors:  Nurun N Borna; Yoshihito Kishita; Kaori Ishikawa; Kazuto Nakada; Jun-Ichi Hayashi; Yoshimi Tokuzawa; Masakazu Kohda; Hiromi Nyuzuki; Yzumi Yamashita-Sugahara; Takashi Nasu; Atsuhito Takeda; Kei Murayama; Akira Ohtake; Yasushi Okazaki
Journal:  J Hum Genet       Date:  2017-01-26       Impact factor: 3.172

8.  Down-regulation of hepatic urea synthesis by oxypurines: xanthine and uric acid inhibit N-acetylglutamate synthase.

Authors:  Itzhak Nissim; Oksana Horyn; Ilana Nissim; Yevgeny Daikhin; Ljubica Caldovic; Belen Barcelona; Javier Cervera; Mendel Tuchman; Marc Yudkoff
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

9.  Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation.

Authors:  Ayman W El-Hattab; Jean W Hsu; Lisa T Emrick; Lee-Jun C Wong; William J Craigen; Farook Jahoor; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2012-01-24       Impact factor: 4.797

Review 10.  Review of clinical trials for mitochondrial disorders: 1997-2012.

Authors:  Douglas S Kerr
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.